Title:
USE OF IMIDAZOLINONE DERIVATIVE COMBINED WITH DOXORUBICIN IN TREATMENT OF TUMORS
Document Type and Number:
WIPO Patent Application WO/2024/017220
Kind Code:
A1
Abstract:
Provided is a use of a compound represented by general formula (I) in combination with doxorubicin in the preparation of an anti-cancer drug.
More Like This:
Inventors:
YE FEI (CN)
WEI YONGGANG (CN)
XU XUEZHEN (CN)
LIU BING (CN)
SU GUIZHUAN (CN)
GAO ZHIWEN (CN)
SUN YI (CN)
WEI YONGGANG (CN)
XU XUEZHEN (CN)
LIU BING (CN)
SU GUIZHUAN (CN)
GAO ZHIWEN (CN)
SUN YI (CN)
Application Number:
PCT/CN2023/107814
Publication Date:
January 25, 2024
Filing Date:
July 18, 2023
Export Citation:
Assignee:
CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/704; A61K9/127; A61K31/522; A61P35/00; C07D473/02
Domestic Patent References:
| WO2021209055A1 | 2021-10-21 |
Foreign References:
| US20200016181A1 | 2020-01-16 | |||
| CN103298814A | 2013-09-11 | |||
| CN103649085A | 2014-03-19 | |||
| US20160002241A1 | 2016-01-07 |
Other References:
GOLDBERG, F. W. ET AL.: "The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- a]pyridin-6-yl)amino]-9-(tetrahydro -2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA- PK ) Inhibitor", J. MED. CHEM., vol. 63, 18 December 2019 (2019-12-18), pages 3461 - 3471, XP055826430, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01684
Attorney, Agent or Firm:
BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF: